Stien De Coninck

Stien De Coninck

Auto-generated profile, based on publicly available information

Stien De Coninck

Department of Biomolecular Medicine, Laboratory of Normal and Malignant Hematopoiesis, Ghent University, Ghent, Belgium

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
JRJuliette Roels
Juliette Roels
MTMorgan Thénoz
Morgan Thénoz
BSBronisława Szarzyńska
Bronisława Szarzyńska
MLMattias Landfors
Mattias Landfors
SCStien De Coninck
Stien De Coninck
PVPieter Van Vlierberghe
Pieter Van Vlierberghe
Cancer cells display DNA hypermethylation at specific CpG islands in comparison with their normal healthy counterparts, but the mechanism that drives this so-called CpG island methylator phenotype (CIMP) remains poorly understood. Here, we show that CpG island methylation in human T-cell acute lymphoblastic leukemia (T-ALL) mainly occurs at promoters of Polycomb Repressor Complex 2 (PRC2) target genes that are not expressed in normal or malignant T cells and that display a reciprocal association with H3K27me3 binding. In addition, we reveal that this aberrant methylation profile reflects the epigenetic history of T-ALL and is established already in preleukemic, self-renewing thymocytes that precede T-ALL development. Finally, we unexpectedly uncover that this age-related CpG island hypermethylation signature in T-ALL is completely resistant to the FDA-approved hypomethylating agent decitabine. Altogether, we provide conceptual evidence for the involvement of a preleukemic phase characterized by self-renewing thymocytes in the pathogenesis of human T-ALL. Significance: We developed a DNA methylation signature that reveals the epigenetic history of thymocytes during T-cell transformation. This human signature was recapitulated by murine self-renewing preleukemic thymocytes that build an age-related CpG island hypermethylation phenotype, providing conceptual evidence for the involvement of a preleukemic thymic phase in human T-cell leukemia. This article is highlighted in the In This Issue feature, p. 215

29 May 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
SCStien De Coninck
Stien De Coninck
JRJuliette Roels
Juliette Roels
BLBéatrice Lintermans
Béatrice Lintermans
STSara T’sAs
Sara T’sAs
TTTom Taghon
Tom Taghon
PVPieter Van Vlierberghe
Pieter Van Vlierberghe

4 April 2023
Verified
Other
Open access
JRJuliette Roels
Juliette Roels
MTMorgan Thénoz
Morgan Thénoz
BSBronisława Szarzyńska
Bronisława Szarzyńska
MLMattias Landfors
Mattias Landfors
SCStien De Coninck
Stien De Coninck
PVPieter Van Vlierberghe
Pieter Van Vlierberghe

4 April 2023
Verified
Other
Open access
JRJuliette Roels
Juliette Roels
MTMorgan Thénoz
Morgan Thénoz
BSBronisława Szarzyńska
Bronisława Szarzyńska
MLMattias Landfors
Mattias Landfors
SCStien De Coninck
Stien De Coninck
PVPieter Van Vlierberghe
Pieter Van Vlierberghe

4 April 2023
Verified
Other
Open access
JRJuliette Roels
Juliette Roels
MTMorgan Thénoz
Morgan Thénoz
BSBronisława Szarzyńska
Bronisława Szarzyńska
MLMattias Landfors
Mattias Landfors
SCStien De Coninck
Stien De Coninck
PVPieter Van Vlierberghe
Pieter Van Vlierberghe
Cancer cells display DNA hypermethylation at specific CpG islands in comparison with their normal healthy counterparts, but the mechanism that drives this so-called CpG island methylator phenotype (CIMP) remains poorly understood. Here, we show that CpG island methylation in human T-cell acute lymphoblastic leukemia (T-ALL) mainly occurs at promoters of Polycomb Repressor Complex 2 (PRC2) target genes that are not expressed in normal or malignant T cells and that display a reciprocal association with H3K27me3 binding. In addition, we reveal that this aberrant methylation profile reflects the epigenetic history of T-ALL and is established already in preleukemic, self-renewing thymocytes that precede T-ALL development. Finally, we unexpectedly uncover that this age-related CpG island hypermethylation signature in T-ALL is completely resistant to the FDA-approved hypomethylating agent decitabine. Altogether, we provide conceptual evidence for the involvement of a preleukemic phase characterized by self-renewing thymocytes in the pathogenesis of human T-ALL.Significance:We developed a DNA methylation signature that reveals the epigenetic history of thymocytes during T-cell transformation. This human signature was recapitulated by murine self-renewing preleukemic thymocytes that build an age-related CpG island hypermethylation phenotype, providing conceptual evidence for the involvement of a preleukemic thymic phase in human T-cell leukemia.This article is highlighted in the In This Issue feature, p. 215

4 April 2023
Verified
Other
Open access
JRJuliette Roels
Juliette Roels
MTMorgan Thénoz
Morgan Thénoz
BSBronisława Szarzyńska
Bronisława Szarzyńska
MLMattias Landfors
Mattias Landfors
SCStien De Coninck
Stien De Coninck
PVPieter Van Vlierberghe
Pieter Van Vlierberghe